Norma Carmen
Gutiérrez Gutiérrez
Profesora Asociada CC. Salud
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (49)
2024
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
2022
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
Genomics of Plasma Cell Leukemia
Cancers, Vol. 14, Núm. 6
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Experimental Hematology and Oncology, Vol. 11, Núm. 1
-
TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399
-
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354
2021
-
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cells, Vol. 10, Núm. 2
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Effect of graphene family materials on multiple myeloma and non-Hodgkin's lymphoma cell lines
Materials, Vol. 13, Núm. 15, pp. 1-21
-
FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182
2019
-
Factors regulating microRNA expression and function in multiple myeloma
Non-coding RNA, Vol. 5, Núm. 1
-
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
Blood, Vol. 133, Núm. 11, pp. 1217-1221
-
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
Blood Cancer Journal, Vol. 9, Núm. 12
2018
-
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility
Haematologica, Vol. 103, Núm. 5, pp. 880-889
2017
-
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma
Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Targeting ongoing DNA damage in multiple myeloma: Effects of DNA damage response inhibitors on plasma cell survival
Frontiers in Oncology, Vol. 7, Núm. MAY
-
The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care
Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238
2016
-
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262